TABLE OF CONTENTS
1 INTRODUCTION 68
1.1 OBJECTIVES OF THE STUDY 68
1.2 MARKET DEFINITION 68
1.3 OVERVIEW 68
1.4 CURRENCY AND PRICING 70
1.5 LIMITATIONS 70
1.6 MARKETS COVERED 71
2 MARKET SEGMENTATION 74
2.1 MARKETS COVERED 74
2.2 GEOGRAPHICAL SCOPE 75
2.3 YEARS CONSIDERED FOR THE STUDY 76
2.4 DBMR TRIPOD DATA VALIDATION MODEL 77
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.6 MULTIVARIATE MODELLING 81
2.7 MARKET APPLICATION COVERAGE GRID 82
2.8 PRODUCT LIFELINE CURVE 83
2.9 DBMR MARKET POSITION GRID 84
2.10 VENDOR SHARE ANALYSIS 86
2.11 SECONDARY SOURCES 87
2.12 ASSUMPTIONS 87
3 EXECUTIVE SUMMARY 88
4 PREMIUM INSIGHTS 91
4.1 PORTERS FIVE FORCES 94
4.2 PESTEL ANALYSIS 95
4.3 INDUSTRY INSIGHTS 96
4.4 CONCLUSION 97
5 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 98
6 MARKET OVERVIEW 100
6.1 DRIVERS 102
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 102
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 102
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 103
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 103
6.2 RESTRAINTS 104
6.2.1 HIGH COST OF FISH TESTING 104
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 104
6.3 OPPORTUNITIES 105
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 105
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 105
6.4 CHALLENGES 106
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 106
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 106
7 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 107
7.1 OVERVIEW 108
7.2 CONSUMABLES 111
7.2.1 FISH PROBE 111
7.2.1.1 FISH PROBE, BY PROBE TYPE 112
7.2.1.1.1 CHROMOSOME FISH PROBE 112
7.2.1.1.2 SPLIT FISH PROBES 112
7.2.1.1.3 TRANSLOCATION FISH PROBES 112
7.2.1.1.4 SUBTELOMERE FISH PROBES 112
7.2.1.1.5 PRENATAL FISH PROBES 112
7.2.1.1.6 OTHERS PROBES 113
7.2.1.2 FISH PROBE, BY TECHNOLOGY 113
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 113
7.2.1.2.2 C-ISH 113
7.2.1.2.3 D-ISH 113
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 113
7.2.1.2.5 OTHERS 113
7.2.1.3 FISH PROBE, BY TYPE 114
7.2.1.3.1 RNA 114
7.2.1.3.1.1 MRNA 114
7.2.1.3.1.2 MIRNA 114
7.2.1.3.1.3 OTHERS 115
7.2.1.3.2 DNA 115
7.2.2 ACCESSORY KITS & REAGENTS 115
7.2.2.1 KITS 115
7.2.2.2 BUFFER 115
7.2.2.3 DYES 115
7.2.2.4 OTHERS 116
7.3 INSTRUMENT 116
7.3.1 STANDALONE 117
7.3.2 PORTABLE 117
7.3.3 HANDHELD 117
7.4 SOFTWARE 117
8 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 118
8.1 OVERVIEW 119
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 122
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 123
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 124
8.5 OTHERS 125
9 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 126
9.1 OVERVIEW 127
9.2 CANCER RESEARCH 130
9.2.1 CANCER RESEARCH, BY CANCER TYPE 131
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 131
9.2.1.1.1 BREAST CANCER 131
9.2.1.1.2 LUNG CANCER 131
9.2.1.1.3 MELANOMA 132
9.2.1.1.4 PROSTRATE CANCER 132
9.2.1.1.5 OVARIAN CANCER 132
9.2.1.1.6 OTHERS 132
9.2.1.2 HEMATOPOETIC MALIGNANCIES 132
9.2.1.2.1 LEUKEMIA 132
9.2.1.2.2 MULTIPLE MYELOMA 133
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 133
9.2.2 CANCER RESEARCH, BY PRODUCT 133
9.2.2.1 CONSUMABLES 133
9.2.2.2 INSTRUMENTS 133
9.2.2.3 SOFTWARE 133
9.3 GENETIC RESEARCH 134
9.3.1 CYTOGENETICS 135
9.3.2 CHROMOSOMAL ABNORMALITIES 135
9.3.3 OTHERS 135
9.4 INFECTIOUS DISEASE 135
9.4.1 CONSUMABLES 136
9.4.2 INSTRUMENTS 136
9.4.3 SOFTWARE 136
9.5 PERSONALIZED MEDICINE 136
9.6 OTHERS 137
10 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 138
10.1 OVERVIEW 139
10.2 RESEARCH 142
10.2.1 INSTRUMENTS 142
10.2.2 CONSUMABLES 143
10.2.3 SOFTWARE 143
10.3 CLINICAL 143
10.3.1 CONSUMABLES 144
10.3.2 INSTRUMENT 144
10.3.3 SOFTWARE 144
10.4 COMPANION DIAGNOSTIC 144
10.4.1 CONSUMABLES 145
10.4.2 INSTRUMENT 145
10.4.3 SOFTWARE 145
11 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 146
11.1 OVERVIEW 147
11.2 DIAGNOSTIC LABORATORIES 150
11.3 HOSPITALS & CLINICS 150
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 151
11.5 ACADEMIC & RESEARCH INSTITUTES 152
11.6 CONTRACT RESEARCH ORGANIZATIONS 152
11.7 OTHERS 153
12 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 154
12.1 OVERVIEW 155
12.2 RETAIL SALES 158
12.3 ONLINE SALES 158
12.4 DIRECT TENDER 159
12.5 OTHERS 160
13 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 161
13.1 OVERVIEW 162
13.2 NORTH AMERICA 167
13.2.1 U.S. 180
13.2.2 CANADA 188
13.2.3 MEXICO 196
13.3 EUROPE 204
13.3.1 GERMANY 218
13.3.2 U.K. 226
13.3.3 ITALY 234
13.3.4 FRANCE 242
13.3.5 SPAIN 250
13.3.6 RUSSIA 258
13.3.7 SWITZERLAND 266
13.3.8 TURKEY 274
13.3.9 BELGIUM 282
13.3.10 NETHERLANDS 290
13.3.11 DENMARK 298
13.3.12 SWEDEN 306
13.3.13 POLAND 314
13.3.14 NORWAY 322
13.3.15 FINLAND 330
13.3.16 REST OF EUROPE 338
13.4 ASIA-PACIFIC 339
13.4.1 JAPAN 353
13.4.2 CHINA 361
13.4.3 SOUTH KOREA 369
13.4.4 INDIA 377
13.4.5 SINGAPORE 385
13.4.6 THAILAND 393
13.4.7 INDONESIA 402
13.4.8 MALAYSIA 410
13.4.9 PHILIPPINES 418
13.4.10 AUSTRALIA 426
13.4.11 NEW ZEALAND 434
13.4.12 VIETNAM 442
13.4.13 TAIWAN 450
13.4.14 REST OF ASIA-PACIFIC 458
13.5 SOUTH AMERICA 459
13.5.1 BRAZIL 471
13.5.2 ARGENTINA 479
13.5.3 REST OF SOUTH AMERICA 487
13.6 MIDDLE EAST AND AFRICA 488
13.6.1 SOUTH AFRICA 502
13.6.2 SAUDI ARABIA 512
13.6.3 EGYPT 520
13.6.4 UAE 529
13.6.5 KUWAIT 537
13.6.6 QATAR 546
13.6.7 OMAN 554
13.6.8 BAHRAIN 563
13.6.9 REST OF MIDDLE EAST AND AFRICA 571
14 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 572
14.1 COMPANY SHARE ANALYSIS: GLOBAL 572
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 573
14.3 COMPANY SHARE ANALYSIS: EUROPE 574
14.4 COMPANY SHARE ANALYSIS: EUROPE 575
15 SWOT ANALYSIS 576
16 COMPANY PROFILE 577
16.1 MERCK KGAA 577
16.1.1 COMPANY SNAPSHOT 577
16.1.2 REVENUE ANALYSIS 577
16.1.3 COMPANY SHARE ANALYSIS 578
16.1.4 PRODUCT PORTFOLIO 578
16.1.5 RECENT DEVELOPMENT 578
16.2 ABBOTT 579
16.2.1 COMPANY SNAPSHOT 579
16.2.2 REVENUE ANALYSIS 579
16.2.3 COMPANY SHARE ANALYSIS 580
16.2.4 PRODUCT PORTFOLIO 580
16.2.5 RECENT DEVELOPMENT 581
16.3 AGILENT TECHNOLOGIES, INC. 582
16.3.1 COMPANY SNAPSHOT 582
16.3.2 REVENUE ANALYSIS 582
16.3.3 COMPANY SHARE ANALYSIS 583
16.3.4 PRODUCT PORTFOLIO 583
16.3.5 RECENT DEVELOPMENT 583
16.4 F. HOFFMANN-LA ROCHE LTD. 584
16.4.1 COMPANY SNAPSHOT 584
16.4.2 REVENUE ANALYSIS 584
16.4.3 COMPANY SHARE ANALYSIS 585
16.4.4 PRODUCT PORTFOLIO 585
16.4.5 RECENT DEVELOPMENT 585
16.5 THERMO FISCHER SCIENTIFIC INC. 586
16.5.1 COMPANY SNAPSHOT 586
16.5.2 REVENUE ANALYSIS 586
16.5.3 COMPANY SHARE ANALYSIS 587
16.5.4 PRODUCT PORTFOLIO 587
16.5.5 RECENT DEVELOPMENT 588
16.6 ABCAM PLC. 589
16.6.1 COMPANY SNAPSHOT 589
16.6.2 REVENUE ANALYSIS 589
16.6.3 COMPANY SHARE ANALYSIS 590
16.6.4 PRODUCT PORTFOLIO 590
16.6.5 RECENT DEVELOPMENTS 590
16.7 ABNOVA CORPORATION 592
16.7.1 COMPANY SNAPSHOT 592
16.7.2 PRODUCT PORTFOLIO 592
16.7.3 RECENT DEVELOPMENT 592
16.8 BIO SB 593
16.8.1 COMPANY SNAPSHOT 593
16.8.2 PRODUCT PORTFOLIO 593
16.8.3 RECENT DEVELOPMENT 593
16.9 BIOCARE MEDICAL, LLC 594
16.9.1 COMPANY SNAPSHOT 594
16.9.2 PRODUCT PORTFOLIO 594
16.9.3 RECENT DEVELOPMENT 595
16.10 BIOCAT GMBH 596
16.10.1 COMPANY SNAPSHOT 596
16.10.2 PRODUCT PORTFOLIO 596
16.10.3 RECENT DEVELOPMENT 597
16.11 BIODOT 598
16.11.1 COMPANY SNAPSHOT 598
16.11.2 PRODUCT PORTFOLIO 598
16.11.3 RECENT DEVELOPMENT 598

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.